Selective serotonin reuptake inhibitor use in first trimester pregnancy and risk of congenital anomalies:A EUROmediCAT case-malformed control study in 12 countries
Breidge Boyle(Queen's University Belfast), Helen Dolk(University of Ulster), Awi Wiesel(Johannes Gutenberg University Mainz), Maria Loane(University of Ulster), Marian K. Bakker(University Medical Center Groningen), Ester Garne(University of Southern Denmark), Kari Klungsøyr(Norwegian Institute of Public Health), Vera Nelen(Provincial Institute for Hygiene), Anna Pierini(Istituto di Fisiologia Clinica), Babak Khoshnood(Inserm), Larraitz Arriola(Basque Government), Miriam Gatt(Ministry for Health), MC Addor, Dawn Tucker, Sheila Jordan, Amanda J. Neville(University of Ferrara), Anke Rißmann(Otto-von-Guericke-Universität Magdeburg)
IRIS
January 1, 2015
Cited by 0
Related Papers
UK health performance: findings of the Global Burden of Disease Study 2010
|The Lancet|2013|557
Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC)
|American Journal of Clinical Nutrition|2015|360
Epidemiology of congenital diaphragmatic hernia in Europe: a register-based study
|Archives of Disease in Childhood Fetal & Neonatal|2014|311
Long term trends in prevalence of neural tube defects in Europe: population based study
|BMJ|2015|247
Associated anomalies in multi‐malformed infants with cleft lip and palate: An epidemiologic study of nearly 6 million births in 23 EUROCAT registries
|American Journal of Medical Genetics Part A|2007|243